Tags

Type your tag names separated by a space and hit enter

Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.

Abstract

Multiple sclerosis (MS) is associated with a wide range of disease symptoms and amongst these, spasticity is one of the most disabling and has the greatest impact on patient well-being and quality of life. Until now, available drug therapies for spasticity appear to have limited benefit and are often associated with poor tolerability. In a recent Spanish survey it was noted that multidrug therapy and a low control rate were common features for a large proportion of patients with MS-related spasticity, suggesting that currently available monotherapies lack significant activity. Sativex is a 1:1 mixture of δ-9-tetrahydrocannabinol and cannabidiol derived from Cannabis sativa chemovars, which is available as an oromucosal spray. Clinical experience with Sativex in patients with MS-related spasticity is steadily accumulating. Results from randomized, controlled trials have reported a reduction in the severity of symptoms associated with spasticity, leading to a better ability to perform daily activities and an improved perception of patients and their carers regarding functional status. These are highly encouraging findings that provide some much needed optimism for the treatment of this disabling and often painful symptom of MS.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    Department of Neurology, Neuroimmunology and Multiple Sclerosis Unit, Health Research Institute (IdiPAZ), University Hospital La Paz/Autónoma University of Madrid, Madrid, Spain. orejacbn@gmail.com

    Source

    Expert review of neurotherapeutics 12:4 Suppl 2012 Apr pg 3-8

    MeSH

    Cannabidiol
    Cannabinoids
    Clinical Trials as Topic
    Dronabinol
    Drug Combinations
    Humans
    Multiple Sclerosis
    Muscle Spasticity
    Plant Extracts
    Quality of Life
    Spain

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    22509985

    Citation

    Oreja-Guevara, Celia. "Clinical Efficacy and Effectiveness of Sativex, a Combined Cannabinoid Medicine, in Multiple Sclerosis-related Spasticity." Expert Review of Neurotherapeutics, vol. 12, no. 4 Suppl, 2012, pp. 3-8.
    Oreja-Guevara C. Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity. Expert Rev Neurother. 2012;12(4 Suppl):3-8.
    Oreja-Guevara, C. (2012). Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity. Expert Review of Neurotherapeutics, 12(4 Suppl), pp. 3-8. doi:10.1586/ern.12.11.
    Oreja-Guevara C. Clinical Efficacy and Effectiveness of Sativex, a Combined Cannabinoid Medicine, in Multiple Sclerosis-related Spasticity. Expert Rev Neurother. 2012;12(4 Suppl):3-8. PubMed PMID: 22509985.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity. A1 - Oreja-Guevara,Celia, PY - 2012/4/19/entrez PY - 2012/4/25/pubmed PY - 2012/8/11/medline SP - 3 EP - 8 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 12 IS - 4 Suppl N2 - Multiple sclerosis (MS) is associated with a wide range of disease symptoms and amongst these, spasticity is one of the most disabling and has the greatest impact on patient well-being and quality of life. Until now, available drug therapies for spasticity appear to have limited benefit and are often associated with poor tolerability. In a recent Spanish survey it was noted that multidrug therapy and a low control rate were common features for a large proportion of patients with MS-related spasticity, suggesting that currently available monotherapies lack significant activity. Sativex is a 1:1 mixture of δ-9-tetrahydrocannabinol and cannabidiol derived from Cannabis sativa chemovars, which is available as an oromucosal spray. Clinical experience with Sativex in patients with MS-related spasticity is steadily accumulating. Results from randomized, controlled trials have reported a reduction in the severity of symptoms associated with spasticity, leading to a better ability to perform daily activities and an improved perception of patients and their carers regarding functional status. These are highly encouraging findings that provide some much needed optimism for the treatment of this disabling and often painful symptom of MS. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/22509985/Clinical_efficacy_and_effectiveness_of_Sativex_a_combined_cannabinoid_medicine_in_multiple_sclerosis_related_spasticity_ L2 - http://www.tandfonline.com/doi/full/10.1586/ern.12.11 DB - PRIME DP - Unbound Medicine ER -